Clinical evidence for the cardiovascular benefits of angiotensin receptor blockers

Area of Science:

• Cardiovascular Medicine
• Pharmacology

Background:

• The renin-angiotensin-aldosterone system (RAAS) and its effector peptide, angiotensin II (Ang II), are key targets for cardiovascular disease (CVD) management.
• Angiotensin II contributes to CVD progression, morbidity, and mortality.
• Current strategies include ACE inhibitors (ACE-Is) and Ang II receptor blockers (ARBs).

Purpose of the Study:

• To evaluate the role of targeting Ang II in slowing CVD progression.
• To compare the efficacy and tolerability of ACE inhibitors versus Ang II receptor blockers.
• To explore the potential of ARBs in preventing or delaying diabetes.

Main Methods:

• Review of numerous clinical studies and trials investigating ACE inhibitors and ARBs.
• Analysis of outcomes related to morbidity and mortality in cardiovascular disease patients.
• Assessment of tolerability profiles, including adverse effects like angioedema and cough.

Main Results:

• ACE inhibitors demonstrate benefits in reducing CVD morbidity and mortality but have tolerability concerns.
• ARBs provide a more specific and complete blockade of Ang II's detrimental effects with generally better tolerability.
• Clinical trials indicate ARBs are associated with positive outcomes across the CVD spectrum and may help prevent or delay diabetes.

Conclusions:

• Targeting Ang II via ARBs is a promising strategy for managing cardiovascular disease.
• ARBs offer a favorable tolerability profile compared to ACE inhibitors.
• Further trials are ongoing to define the definitive role of ARBs in reducing CVD morbidity and mortality.